[1]Dammann R,Li C,Yoon JH,et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3[J].Nat Genet, 2000,25(3):315-319.
[2]Lerman MI,Minna JD.The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppre-ssor genes[J]. Cancer Res, 2000,60(21):6116-6133.
[3]van der Weyden L,Adams DJ.The Ras-assoeiation domain family(RASSF) members and their role in human tumourigenesis[J].Biochim Biophys Aeta, 2007,1776(1):58-85.
[4]Verma SK, Ganesan TS, Parker PJ. The tumour suppressor RASSF1A is a novel substrate of PKC[J].FEBS Lett, 2008,582(15):2270-2276.
[5]Levitt NC, Hickson ID. Caretaker tumour suppressor genes that defend genome integrity[J].Trends Mol Med, 2002,8(4):179-186.
[6]Shiloh Y. ATM and related protein kinases: safeguarding genome integrity[J]. Nat Rev Cancer, 2003,3(3):155-168.
[7]Thaler S, Hhnel PS, Schad A, et al. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt[J]. Cancer Res, 2009,69(5):1748-1757.
[8]Khokhlatchev A,Rabizadeh S,Xavier R,et al.Identification of a novel Ras-regulated proapoptotic pathway[J]. Curr Bio,2002,12(4):253-265.
[9]Pallarés J,Velasco A,Eritja N,et al.Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma[J]. Mod Pathol,2008,21(6):691-699.
[10]Whang YM, Kim YH, Kim JS, et al. RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression[J]. Cancer Res, 2005,65(9):3682-3690.
[11]Yoo YA,Na AR,Lee MS,et al.RASSF1A suppresses oneogenic H-Ras-induced c-Jun N-terminal kinase activation[J].Int J Oneol,2006,29(6):1541-1547.
[12]Khokhlatchev A, Rabizadeh S, Xavier R,et al. Identification of a novel Ras-regulated proapoptotic pathway[J].Curr Biol, 2002,12(4):253-265.
[13]Creasy CL, Ambrose DM, Chernoff J. The Ste20-like protein kinase, Mst1, dimerizes and contains an inhibitory domain[J]. J Biol Chem, 1996,271(35):21049-21053.
[14]Oh HJ, Lee KK, Song SJ,et al.Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis[J].Cancer Res, 2006,66(5):2562-2569.
[15]Guo C, Tommasi S, Liu L,et al. RASSF1A is part of a complex similar to the drosophila Hippo/Salvador/Lats tumor-suppressor network[J]. Curr Biol, 2007,17(8):700-705.
[16]Rabizadeh S, Xavier RJ, Ishiguro K,et al.The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death[J]. J Biol Chem, 2004,279(28):29247-29254.
[17]Baksh S, Tommasi S, Fenton S,et al. The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death[J].Mol Cell, 2005,18(6):637-650.
[18]Vos MD,Dallol A,Eckfeld K,et al.The RASSF1A tumor suppressor activates Bax via MOAP-1[J].J Biol Chem,2006,281(8):4557-4563.
[19]Foley CJ, Freedman H, Choo SL,et al. Dynamics of RASSF1A/MOAP-1 association with death receptors[J]. Mol Cell Biol, 2008,28(14):4520-4535.
[20]Harvey K, Tapon N.The Salvador-Warts-Hippo pathway-an emerging tumour-suppressor network[J].Nat Rev Cancer, 2007,7(3):182-191.
[21]Whitehurst AW, Ram R, Shivakumar L,et al.The RASSF1A tumor suppressor restrains anaphase-promoting complex/cyclosome activity during the G1/S phase transition to promote cell cycle progression in human epithelial cells[J]. Mol Cell Biol, 2008,28(10):3190-3197.
[22]Ura S,Nishina H,Gotoh Y,et al. Activation of the JNK pathway by MST1 is essential and sufficient for the induction of chromatin condensation during apoptosis[J].Mol Cell Biol, 2007,27(15):5514-5522.
[23]Fenton SL, Dallol A, Agathanggelou A, et al.Identification of the E1A-regulated transcription factor p120E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene[J]. Cancer Res, 2004,64(1):102-107.
[24]Ahmed-Choudhury J, Agathanggelou A, Fenton SL,et al. Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the cyclin A2 promoter[J]. Cancer Res, 2005,65(7):2690-2697.
[25]Song MS, Song SJ, Ayad NG,et al. The tumor suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex[J]. Nat Cell Biol, 2004,6(2):129-137.
[26]Song SJ, Song MS, Kim SJ,et al. Aurora A regulates prometaphase progression by inhibiting the ability of RASSF1A to suppress APC-Cdc20 activity[J]. Cancer Res, 2009,69(6):2314-2323.
[27]Yu H. Cdc20: a WD40 activator for a cell cycle degradation machine[J]. Mol Cell, 2007,27(1):3-16.
[28]Vos MD, Martinez A, Elam C, et al.A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability[J]. Cancer Res, 2004,64(12):4244-4250.
[29]Shivakumar L, Minna J, Sakamaki T,et al.The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation[J]. Mol Cell Biol, 2002,22(12):4309-4318.
[30]Wassmann K,Benezra R. Mitotic checkpoints: from yeast to cancer[J]. Cold Spring Harb Symp Quant Biol, 2000,65(4):361-368.
[31]Song MS, Chang JS, Song SJ,et al.The centrosomal protein RAS association domain family protein 1A (RASSF1A)-binding protein 1 regulates mitotic progression by recruiting RASSF1A to spindle poles[J]. J Biol Chem, 2005,280(5):3920-3927.
[32]Armesilla AL, Williams JC, Buch MH,et al. Novel functional interaction between the plasma membrane Ca2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1)[J]. J Biol Chem, 2004,279(30):31318-31328.
[33]Wang YC,Yu ZH,Liu C,et al. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients[J]. World J Gastroenterol, 2008,14(19):3074-3080.
[34]Kioulafa M, Kaklamanis L, Mavroudis D,et al. Prognostic significance of RASSF1A promoter methylation in operable breast cancer[J]. Clin Biochem,2009,42(10-11):970-975.
[35]Chan KC,Lai PB,Mok TS,et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma[J]. Clin Chem, 2008,54(9):1528-1536.
[36]Ellinger J,Albers P,Perabo FG,et al. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer[J].J Urol, 2009, 182(1):324-329.
|